Clinical validation of a 13-lead electrocardiogram derived from a self-applicable 3-lead recording for diagnosis of myocardial supply ischaemia and common non-ischaemic electrocardiogram abnormalities at rest.
Acute coronary syndrome
Diagnosis
Handheld ECG device
Mobile app
Personalized health
Pre-hospital
Journal
European heart journal. Digital health
ISSN: 2634-3916
Titre abrégé: Eur Heart J Digit Health
Pays: England
ID NLM: 101778323
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
27
06
2022
revised:
22
09
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
In this study, we compare the diagnostic accuracy of a standard 12-lead electrocardiogram (ECG) with a novel 13-lead ECG derived from a self-applicable 3-lead ECG recorded with the right exploratory left foot (RELF) device. The 13th lead is a novel age and sex orthonormalized computed ST (ASO-ST) lead to increase the sensitivity for detecting ischaemia during acute coronary artery occlusion. A database of simultaneously recorded 12-lead ECGs and RELF recordings from 110 patients undergoing coronary angioplasty and 30 healthy subjects was used. Five cardiologists scored the learning data set and five other cardiologists scored the validation data set. In addition, the presence of non-ischaemic ECG abnormalities was compared. The accuracy for detection of myocardial supply ischaemia with the derived 12 leads was comparable with that of the standard 12-lead ECG ( A self-applicable and easy-to-use 3-lead RELF device can compute a 12-lead ECG plus an ischaemia-specific 13th lead that is, compared with the standard 12-lead ECG, more accurate for the visual diagnosis of myocardial supply ischaemia by cardiologists.
Identifiants
pubmed: 36710895
doi: 10.1093/ehjdh/ztac062
pii: ztac062
pmc: PMC9779790
doi:
Types de publication
Journal Article
Langues
eng
Pagination
548-558Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.
Déclaration de conflit d'intérêts
Conflict of interest: P.G. and M.E.H. declare the patents EP3003140A1 (European Patent Office), CA2912476C (Canada), WO2014187998A1 (WIPO [PCT]), US9867577B2 (USA). All other authors declare no competing interests.
Références
Curr Opin Cardiol. 2012 Jul;27(4):327-30
pubmed: 22565144
Eur Heart J. 2018 Apr 1;39(13):1065-1074
pubmed: 29452351
IEEE Rev Biomed Eng. 2014;7:126-42
pubmed: 23708809
J Am Coll Cardiol. 1985 Dec;6(6):1273-9
pubmed: 4067105
Eur Heart J Digit Health. 2021 Feb 20;2(1):127-134
pubmed: 36711180
J Electrocardiol. 2007 Jul;40(3):251-6
pubmed: 17292385
Am J Cardiol. 2001 Apr 15;87(8):970-4; A4
pubmed: 11305988
Can Med Assoc J. 1978 Oct 7;119(7):745-8
pubmed: 709476
Europace. 2021 Aug 6;23(8):1179-1191
pubmed: 33564873
BMC Res Notes. 2012 Jan 20;5:52
pubmed: 22264277
Am Heart J. 2010 Dec;160(6):995-1003, 1003.e1-8
pubmed: 21146650
J Am Coll Cardiol. 1999 Sep;34(3):748-53
pubmed: 10483956
Eur Heart J. 2006 Nov;27(21):2499-510
pubmed: 16952926
Lancet Digit Health. 2019 Jun;1(2):e90-e99
pubmed: 33323233
J Am Heart Assoc. 2015 Jan 05;4(1):e001399
pubmed: 25559012
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
J Electrocardiol. 2007 Apr;40(2):120-6
pubmed: 17067621
J Electrocardiol. 2016 Mar-Apr;49(2):192-201
pubmed: 26702768
J Am Heart Assoc. 2020 Jul 7;9(13):e015477
pubmed: 32573319
Sci Rep. 2020 Nov 24;10(1):20495
pubmed: 33235279
Mayo Clin Proc. 2020 May;95(5):1015-1039
pubmed: 32370835